Abstract: The present application provides compositions that are provided within a semi-permeable membrane. The compositions can include a particulate material, such as a cellulose, a sugar alcohol, and nicotine. The composition can provide a fast onset of action of the nicotine in the mouth of a user. In particular, when subjected to an in vitro dissolution test using UV detection, about 30% or more of the total content of the nicotine is released from the composition within 30 minutes.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.

Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.

Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: The present invention relates to a network node (14, 18, 21) and a method of a network node of controlling data delivery to a mobile terminal (11, 12, 13) in case of data rate throttling after having reached a data download cap. The method comprises the steps of acquiring (S101) the data to be delivered to the mobile terminal, receiving (S102) an indication that a data download cap for the mobile terminal has been reached, and buffering (S103) the acquired data. The method further comprises the step of delivering (S104) the buffered data to the mobile terminal in bursts.

Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: Disclosed is a method for oral administration of a liquid containing an active substance to a subject for improved absorption into the subject's bloodstream. It includes the steps of providing a delivery device containing the liquid and having a mouthpiece for directing the liquid in a defined direction during delivery; directing the mouthpiece toward a localized area of the subject's mouth being especially suitable for relatively increased uptake and relatively faster onset of action of the active substance; and delivering a measured amount of the liquid directly to the area using the device. Also disclosed is a spray device that includes a container capable of holding a liquid containing an active substance, and a mouthpiece constructed to dispense the liquid in a defined direction and directly to a localized area of a subject's mouth, the localized area being the oral vestibule.

Abstract: The present invention provides antibody polypeptides with binding specificity for prostate specific antigen (PSA), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies.

Abstract: A safety system for a motor vehicle having at least a front wheel arrangement having one or more wheels and rear wheel arrangement having one or more wheels, the arrangement having: a control unit; and one or more vehicle inertial sensors to detect acceleration experienced by the vehicle, the inertial sensors being connected to the control unit so the control unit receives output signals from the inertial sensors; and one or more vehicle safety systems which may be activated by the control unit, wherein the control unit is configured to process the signals received from the inertial sensors and to determine whether at least one of the wheels of the front and rear wheel arrangements is not in contact with the surface over which the vehicle is driven.

Abstract: A method and network element for providing at least one segment that is of a different length than the actual segment of a media stream and where the segment of a different length comprises data not belonging to the actual segment, wherein the segment of a different length begins with a key frame or contains key frames only.

Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

Abstract: Use of a nicotine-cellulose combination for the preparation of a snuff composition for achievement of a fast onset of action of nicotine after application of the snuff composition to the oral cavity of a subject, wherein the composition has a high release rate so that when subjected to an in vitro dissolution test about 45% or more of the total content of nicotine is released within 30 minutes. Moreover, the invention relates to an improved snuff composition for application to the oral cavity.

Abstract: The present application provides an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein (for example, PSA or hK2) for use in the treatment of prostate cancer, and a method for the treatment of prostate cancer in a patient, the method comprising the step of administering a therapeutically effective amount of an agent comprising or consisting of a binding moiety with specificity for a kallikrein protein to the patient.

Abstract: According to embodiments of the present invention, the user-to-user delay and the zapping delay are reduced by a network element which is configured to provide at least one segment that is of a different length than the actual segment of a media stream and where the segment of a different length comprises data not belonging to the actual segment, wherein the segment of a different length begins with a key frame or contains key frames only. By providing the at least one segment being of a different length than the actual segment, the zapping delay can be reduced, since a key frame will be accessible with a reduced time delay. Further, the user-to-user delay is also reduced since the length of the provided segment is adapted so that subsequent segments of the media stream are sent to the users at substantially the same time.